U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H27N3O2S
Molecular Weight 433.566
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BREXPIPRAZOLE

SMILES

O=C1NC2=C(C=C1)C=CC(OCCCCN3CCN(CC3)C4=CC=CC5=C4C=CS5)=C2

InChI

InChIKey=ZKIAIYBUSXZPLP-UHFFFAOYSA-N
InChI=1S/C25H27N3O2S/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10,17-18H,1-2,11-16H2,(H,26,29)

HIDE SMILES / InChI

Molecular Formula C25H27N3O2S
Molecular Weight 433.566
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is approved for the treatment of schizophrenia, and as an adjunctive treatment for major depressive disorder (MDD). Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).Brexpiprazole is sold under the brand name Rexulti. Although the mechanism of action of brexpiprazole in the treatment of MDD and schizophrenia is unclear, the efficacy of brexpiprazole may be attributed to partial agonist activity at serotonin 1A and dopamine D2 receptors, and antagonist activity at serotonin 2A receptors.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
2015 Oct
Brexpiprazole: First Global Approval.
2015 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Treatment of Schizophrenia The recommended starting dosage for REXULTI (Brexpiprazole) is 1 mg once daily on Days 1 to 4, taken orally with or without food The recommended target REXULTI dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient’s clinical response and tolerability. The maximum recommended daily dosage is 4 mg.
Route of Administration: Oral
In Vitro Use Guide
Brexpiprazole (1.0 uM) increased the number of cells with neurites in PC12 cells. Treatment with brexpiprazole (0.001, 0.01, 0.1 or 1.0 uM) in conjunction with NGF (2.5 ng/ml) increased the number of cells with neurites, in a concentration-dependent manner.
Substance Class Chemical
Created
by admin
on Tue Oct 22 01:50:01 UTC 2019
Edited
by admin
on Tue Oct 22 01:50:01 UTC 2019
Record UNII
2J3YBM1K8C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BREXPIPRAZOLE
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
BREXPIPRAZOLE [WHO-DD]
Common Name English
OPC-34712
Code English
BREXPIPRAZOLE [INN]
Common Name English
BREXPIPRAZOLE [USAN]
Common Name English
BREXPIPRAZOLE [JAN]
Common Name English
REXULTI
Brand Name English
Classification Tree Code System Code
WHO-ATC N05AX16
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
NDF-RT N0000175430
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
Code System Code Type Description
LactMed
913611-97-9
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
CAS
913611-97-9
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
RXCUI
1658314
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY RxNorm
ChEMBL
CHEMBL2105760
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
EPA CompTox
913611-97-9
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
IUPHAR
7672
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
PUBCHEM
11978813
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
WIKIPEDIA
BREXPIPRAZOLE
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
INN
9552
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
DRUG BANK
DB09128
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
EVMPD
SUB91646
Created by admin on Tue Oct 22 01:50:01 UTC 2019 , Edited by admin on Tue Oct 22 01:50:01 UTC 2019
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
METABOLIC ENZYME -> NON-SUBSTRATE
TARGET->PARTIAL AGONIST
BINDING
Ki
METABOLIC ENZYME -> NON-SUBSTRATE
TARGET->PARTIAL AGONIST
Ki
METABOLIC ENZYME -> NON-SUBSTRATE
TARGET -> INHIBITOR
Ki
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
Ki
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE LESS ACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
METABOLITE LESS ACTIVE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC